- Details
- In a discussion hosted by Andrea Miyahira, David Quigley discusses his team's research on the genomic and epigenomic landscape of double-negative metastatic prostate cancer. Dr. Quigley provides insights into the mechanisms behind the disease's resistance to targeted therapy, highlighting the transformation of prostate adenocarcinoma cells towards either maintaining their original nature or transi...
|
- Details
- Hiten Patel talks about the significant role of the Veterans Health Administration in prostate cancer treatment and research. Dr. Patel outlines the formation of prostate cancer centers of excellence within the VA, intended to coordinate efforts to improve oncology care and survival rates for veterans. The Precision Oncology Program for the Cancer of the Prostate (POPCaP), created in partnership w...
|
- Details
- Veda Giri discusses the promising results of the TARGET study in an interview with Alicia Morgans. The study examined an innovative web-based approach to expand genetic testing access for prostate cancer patients. The study addressed the lack of sustainable patient-genetic counselor interaction by implementing a patient-driven web tool, which was proven to be non-inferior to traditional genetic co...
|
- Details
- Andrea Miyahira and Susan Halabi discuss Dr Halabi's prognostic model for overall survival in patients with metastatic castration-resistant prostate cancer. Originating in the early 2000s, the model sought to provide patients with more specific information about their prognoses and categorize them into different risk groups. Dr. Halabi's model comprises eight easily obtainable clinical variables,...
|
- Details
- In this discussion, Susan Halabi shares her unique career journey with Andrea Miyahira. Dr. Halabi discusses her initial interest in medical school, which changed course upon being introduced to biostatistics by a mentor. She has worked on research projects and pursued graduate work in the United States, with a network of influential female scientists and mentors supporting her career progression....
|
- Details
- Leanne Woods-Burnham shares her personal and professional journey in prostate cancer research. Dr. Burnham, a 2020 PCF Young Investigator, focuses on understanding why black patients have more aggressive forms of prostate cancer and worse survival outcomes. Her goal is to develop precision medicine therapies to improve survival for late-stage prostate cancer patients, particularly black men. Influ...
|
- Details
- In this conversation, Isla Garraway discusses the unique aspects of prostate cancer research within the VA healthcare system with Matthew Cooperberg. They highlight the diversity of the veteran population served by the VA, including racial, ethnic, and geographic diversity, and the importance of understanding how prostate cancer impacts different groups. The discussion covers disparities in prosta...
|
- Details
- Andrew Armstrong joins Andrea Miyahira in discussing a retrospective analysis of the prospective multicenter PROPHECY trial of men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide seeking to develop a liquid biopsy using circulating tumor cells (CTCs) that they can associate with outcomes in men with mCRPC and ultimately apply that to a PSMA-tar...
|
- Details
- In a thoughtful conversation between Andrea Miyahira and Elisabeth Heath, they discuss the challenges and opportunities for young women in prostate cancer research and oncology. Dr. Heath emphasizes the importance of self-confidence, sharing her daughter's experience with dwindling female representation in her calculus class. She highlights the need to persevere, regardless of self-doubt or percei...
|
- Details
- Alicia Morgans hosts a discussion with Rahul Aggarwal about his ongoing research on DLL3 targeting BiTE therapy. DLL3 is expressed in an aggressive form of prostate cancer known as neuroendocrine prostate cancer. Dr. Aggarwal's study focuses on using an immunotherapeutic approach to target DLL3, using a compound developed by Amgen that enhances immune response. With 40 patients already enrolled in...
|
